Prognostic Significance of Targeted Magnetic Resonance Coronary Angiography to Predict Cardiac Events in Patients with Known or Suspected Coronary Artery Disease

Yodying Kaolawanich  
Mahidol University

Rawiwan Thongsongsang  
Mahidol University

Thananya Boonyasirinant  (drthananyaa@yahoo.com)  
Mahidol University

Research Article

Keywords: cardiac magnetic resonance imaging, coronary artery disease, magnetic resonance coronary angiography, prognosis

Posted Date: May 14th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-478379/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background Magnetic resonance coronary angiography (MRCA) is one of the most promising tools for noninvasive imaging of coronary arteries without radiation exposure or contrast media administration. However, knowledge about the prognostic value of MRCA is limited.

Methods The study included 389 patients with known or suspected coronary artery disease (CAD) who underwent clinical cardiac magnetic resonance (CMR) including MRCA imaging. The presence of significant coronary artery stenosis was defined by visual estimation of $\geq 50\%$ diameter reduction using targeted MRCA images. Patients were followed up for hard cardiac events (cardiac death or non-fatal myocardial infarction) and major adverse cardiac events (MACE) that also included hospitalization for heart failure and late revascularization (>180 days after the CMR study).

Results Average age was 68±11 years and 48% were male. One hundred and thirty-nine patients had significant stenosis on MRCA. During a median follow-up period of 53.9 months, 23 hard cardiac events and 52 MACE occurred. Patients with significant coronary artery stenosis had higher rates of hard cardiac events (annual event rate, 3.12% versus 0.56%; HR 5.52; 95% CI 2.17-14.01; p<0.001) and MACE (annual event rate, 6.44% vs. 1.83%; HR 3.49; 95% CI 1.98-6.14; p<0.001) than those without significant stenosis. Multivariate analyses identified significant coronary artery stenosis as an independent predictor of hard cardiac events (HR 3.35; 95% CI 1.13-9.96; p=0.03) and MACE (HR 2.00; 95% CI 1.02-3.90; p=0.04). MRCA presented an incremental prognostic value over clinical factors, left ventricular ejection fraction, and myocardial scarring to predict hard cardiac events (p=0.03).

Conclusion Targeted MRCA demonstrated independent and incremental prognostic values to predict future cardiac events in patients with known or suspected CAD.

Introduction

Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide. [1] Diagnosis and risk stratification are crucial elements in the management of CAD. Assessment of coronary artery stenosis is also an important part of comprehensive CAD evaluation. Coronary computed tomography angiography (CCTA) has rapidly emerged as a noninvasive method that provides visualization of the coronary arteries and detection of luminal narrowing. CCTA has excellent diagnostic accuracy as well as providing prognostic value in patients with known or suspected CAD. [2-3] However, several factors are known to deteriorate image quality and interpretation including severe calcification and elevated heart rate. [4-6] Moreover, radiation exposure and the administration of contrast media are recognized limitations of CCTA. Magnetic resonance coronary angiography (MRCA) is currently one of the most promising techniques for noninvasive imaging of coronary arteries. MRCA provides high sensitivity and specificity in the diagnosis of CAD without radiation exposure or contrast media administration. [7-9]
Whole-heart and targeted approaches are the two main acquisition methods for MRCA. The whole-heart technique is mostly performed for visualization of all three major coronary arteries and offers a relatively reduced total examination period. However, the targeted approach provides details of each coronary artery and is more likely to yield higher image quality as well as vessel sharpness. \[10\]

Several studies have addressed the diagnostic accuracy of MRCA, including a recent meta-analysis of more than 20 studies. \[7\] By contrast, the prognostic data of MRCA is very limited. One study demonstrated the prognostic significance of whole-heart MRCA to predict cardiac events in patients with suspected CAD. \[11\] However, sample numbers were relatively small (n=207), and no data were provided on left ventricular (LV) function or late gadolinium enhancement (LGE), which are fundamental parts of routine clinical cardiac magnetic resonance (CMR). \[11\]

In this study, we sought to determine the prognostic value of targeted MRCA combining routine clinical CMR in a larger population of patients with known or suspected CAD.

**Methods**

**Study Population**

Consecutive patients over 18 years of age referred for clinical CMR including MRCA imaging were enrolled between 2010 and 2015. MRCA was performed as a part of our comprehensive CMR protocol for the evaluation of patients with CAD. Detailed medical history was collected on the day of the CMR examination. History of hypertension, diabetes mellitus, hyperlipidemia, CAD, and stroke were defined by recent guidelines. \[12-15\]

Patients were excluded from the study if they had poor MRCA images or their follow-up data could not be obtained. The study was done in accordance with the Declaration of Helsinki. The institutional ethics committee (Siriraj Institutional Review Board [SIRB], Faculty of Medicine Siriraj Hospital, Mahidol University) approved this retrospective study and waived the need for additional written informed consent.

**CMR Protocol**

CMR was performed to assess cardiac function, coronary arteries, and LGE on a 1.5 Tesla Gyroscan NT Philips Scanner (Philips Medical Systems, Best, The Netherlands). Functional study and LGE images were acquired as previously described. \[16\]

**MRCA Imaging** \[17\]

Non-contrast, free-breathing, targeted MRCA scanning was performed with a 32-element cardiac synergy receiver coil. An electrocardiogram (ECG) was synchronized during scanning by a vectorcardiogram using three electrodes placed on the chest wall. \[18\] Imaging of the coronary arteries was acquired in the mid-
diastolic phase of the cardiac cycle. Respiratory motion compensation was performed using the navigator technique by placing a navigator on the right hemidiaphragm. [19]

In the process of coronary artery acquisition, a multi-stack survey was first acquired to provide the location of the navigator and the position of low-resolution MRCA. Multiphase cine images were then performed to determine a subject-specific trigger delay and proper acquisition window during minimal cardiac motion. Next, low-resolution MRCA was acquired by planning the slice in the transverse plane, covering the whole heart from the base to apex. The images from this sequence were used to plan double oblique three-dimensional (D) volume for the right coronary artery (RCA) using the three-point plan-scan tool. The corresponding image plan was then applied to acquire high-resolution 3-D MRCA using spectral pre-saturation with inversion recovery (SPIR).

For coronary artery localization and navigator positioning at the right hemidiaphragm, ECG triggered, free-breathing, multi-stack 2-D segmented gradient echo scans from thoracic transverse, sagittal and coronal images were applied to identify the positions of the heart and diaphragm.

To determine the motion of the coronary arteries, multiphase cine images were obtained in the transverse plane perpendicular to the RCA, using a steady-state free precession (SSFP) pulse sequence. [20] Parameters for MRCA acquisition were echo time: 1.63 milliseconds (ms), repetition time: 3.3 ms, flip angle: 60 degrees, matrix size: 200 x 172, number of cardiac phases: 80 and acceleration factor (SENSE): 2.0. The motion of the RCA was visually assessed by scrolling through the transverse cine images. [20] The rest period of minimal displacement during the diastole period was defined as trigger delay time and optimal acquisition window. These timings were then used for subsequent 3-D coronary acquisitions. [20]

**Image Analysis**

LV volumes and ejection fraction (EF) were quantitatively measured from the stack of short-axis cine images using standard techniques. [16] The presence of hyperenhanced tissue on LGE images, interpreted as representing myocardial scarring, was determined by visual inspection using the American Heart Association (AHA) 17-segment model. [21]

For MRCA images, epicardial coronary artery segmentation was determined according to a modified AHA classification. [22] Similar to the previous investigation, the presence of significant coronary lesions was determined based on visual estimation (≥ 50% diameter reduction). [11]

**Clinical Follow-Up**

Follow-up data were collected from clinical visits and medical records. Patients were followed up for hard cardiac events and major adverse cardiac events (MACE). Hard cardiac events were defined by the composite outcomes of cardiac death and non-fatal MI, while MACE was defined as the composite outcomes of cardiac death, non-fatal MI, hospitalization for heart failure, and late coronary
revascularization (revascularization procedures that occurred more than 180 days after the CMR study). [23]

CMR results may influence decisions regarding revascularization and lead to periprocedural events or death. Therefore, coronary revascularizations that occurred within 180 days after the CMR study or periprocedural events that occurred in the same admission were not considered for analysis.

**Statistical Analysis**

Statistical analyses were performed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA). Continuous variables with normal distribution were presented as mean ± standard deviation (SD), and continuous variables with non-normal distribution were presented as median and interquartile ranges. The normality of the distribution of variables was examined by the Kolmogorov-Smirnov test. Categorical variables were present as absolute numbers and percentages. Differences between patients with and without significant stenosis in terms of clinical baseline and CMR characteristics were compared using the Student's unpaired t-test or the Mann-Whitney U test for continuous variables, while the chi-square test or Fisher’s exact test were used for categorical variables, as appropriate.

Composite outcomes between patients with and without significant stenosis were estimated using the Kaplan-Meier method and compared with the log-rank test. To analyze the predictors of hard cardiac events and MACE, a Cox-regression analysis was performed to assess univariate predictors from baseline characteristics, medications, and CMR parameters. The five most significant predictors identified by the univariate analysis were included as candidate variables in a stepwise selection process. To avoid the potential for overfitting, no more than five variables were included in any multivariate model.

To assess the incremental prognosis values of significant predictors, global chi-square values were calculated after adding predictors in the following order: clinical factors, LVEF, LGE, and MRCA.

The hazard ratios (HRs) and 95% confidence intervals (CIs) of the outcomes were calculated, with a p-value <0.05 considered statistically significant.

**Results**

**Patient Characteristics**

Three hundred and ninety-seven patients were enrolled, 8 were excluded: 6 had uninterpretable MRCA images, and 2 did not have adequate follow-up data. Thus, 389 patients were included for the final analysis. Baseline characteristics of patients with and without significant coronary artery stenosis are listed in Table 1. Average age was 68.1±10.8 years, and 48% were male. The common presenting symptoms were chest pain (34%), dyspnea (16%), and heart failure syndrome. Sixty-one patients had a history of stable CAD, and 12 patients had previous MI.
One hundred and thirty-nine patients had significant stenosis of at least one segment of a coronary artery, while 250 patients were free from significant stenosis. Among the 139 patients with significant stenosis, 66 had single vessel disease, while 73 had multivessel disease. Patients with significant coronary artery stenosis were more likely to have hyperlipidemia, stable CAD, previous MI, and be on antiplatelet and statin therapy (p<0.05 for all). Patients with significant coronary artery stenosis also had lower LVEF and higher prevalence of LGE (p<0.001 for both). Figure 1 demonstrates MRCA findings in a patient with significant coronary artery stenosis.

Follow-Up Results

During a median follow-up period of 53.9 (33.8, 67.9) months, 23 hard cardiac events and 52 MACE occurred. Patients with significant coronary artery stenosis had higher rates of both hard cardiac events (annual event rate, 3.12% vs. 0.56%; HR 5.52; 95% CI 2.17-14.01; p<0.001) and MACE (annual event rate, 6.44% vs. 1.83%; HR 3.49; 95% CI 1.98-6.14; p<0.001) than those without significant stenosis. Table 2 shows cardiac events during follow-up. Kaplan-Meier survival curves for hard cardiac events and MACE are shown in Figure 2.

Univariate and multivariate analyses of predictors for hard cardiac events and MACE are shown in Tables 3 and 4, respectively. The five most significant predictors identified by univariate analysis for hard cardiac events were previous MI, the use of nitrate, LVEF, LGE, and significant coronary artery stenosis on MRCA (p<0.05 for all). History of heart failure, previous MI, LVEF, LGE, and MRCA were the five most significant predictors for MACE (p<0.01 for all). Multivariate analyses showed that history of heart failure (HR 3.28; 95% CI 1.62-6.63; p=0.001), LGE (HR 2.27; 95% CI 1.05-4.91; p=0.03) and MRCA (HR 2.00; 95% CI 1.02-3.90; p=0.04) were independent predictors of MACE (Table 4). For hard cardiac events, only significant coronary artery stenosis on MRCA was an independent predictor (HR 3.55; 95% CI 1.13-9.96; p=0.03) (Table 3).

Figure 3 shows incremental prognostic values of clinical and CMR variables to predict hard cardiac events and MACE. When the prognosis was assessed in a hierarchical manner (clinical only, clinical+LVEF, clinical+LVEF+LGE, and clinical+LVEF+LGE+MRCA), MRCA provided an incremental prognostic value over clinical variables, LVEF, and LGE for hard cardiac events (p=0.03) (Figure 3A) but did not reach a significance for MACE (p=0.17) (Figure 3B).

In this study, targeted MRCA also detected anomalous coronary arteries; two patients had the RCA originated from the left coronary cusp of the aortic valve, while one of these had a malignant type, inter-arterial course with an acute angle requiring surgical managements (Figure 4).

Discussion

Result showed that significant stenosis of the coronary artery assessed by targeted MRCA was a strong and independent predictor of hard cardiac events and MACE in patients with known or suspected CAD.
Targeted MRCA also provided an incremental prognostic value for hard cardiac events over clinical data, LVEF, and myocardial scarring.

**The Use of CMR in Patients with CAD**

Many studies have been published regarding the role of CMR in CAD over the last decade providing important technical advances, large-scale clinical validation and prognostic data.\(^{[24,25]}\) CMR can evaluate global and regional cardiac function, myocardial ischemia and myocardial scarring in one examination. The standard CMR protocol for evaluation of CAD comprises cardiac function, myocardial perfusion and LGE imaging. Coronary artery assessment by MRCA is a novel sequence that can provide additional diagnostic and prognostic value.\(^{[7-9]}\)

**Assessment of Coronary Arteries using MRCA**

MRCA is more technically challenging than CMR of other vascular beds due to several unique issues including small luminal size and near constant motion of coronary arteries, the high level of tortuosity, and surrounding signals from adjacent epicardial fat and myocardium. According to a recent guideline, current roles of MRCA include the evaluation of anomalous coronary arteries and coronary artery aneurysms.\(^{[26]}\) For atherosclerotic disease, CCTA appears to be the standard technique for noninvasive visualization of coronary arteries.\(^{[26]}\) Currently, the CCTA technique offers a sensitive and specific tool for the detection of significant coronary stenosis, and also plays a prognostic role in the prediction of cardiac events.\(^{[2,3]}\) However, exposure to ionizing radiation and contrast agent administration present inherent disadvantages. CTTA use is also limited for patients with heavy coronary artery calcification or high heart rates.\(^{[4-6]}\)

MRCA has some benefits over CCTA. MRCA can assess coronary arteries without exposure to radiation or administration of contrast media. MRCA sequences have undergone considerable technical improvements over time.\(^{[27]}\) A non-contrast enhanced MRCA technique using a 3-D approach is the current standard CMR protocol due to its higher spatial resolution compared to the previous 2-D technique.\(^{[27]}\) Respiratory motion can be overcome by multiple breath-hold or preferably a free-breathing method, with a respiratory navigator gating.

Whole-heart and targeted approaches are the main acquisition modes used at present. Imaging of major coronary arteries by targeted MRCA is performed with several oblique, thin-slab volumes targeting specific coronary arteries, while the whole-heart approach is an alternative method that can visualize all coronary arteries within a single acquisition. A meta-analysis showed that the whole-heart technique had higher specificity (78% versus 57%) with similar sensitivity (89% versus 90%) to detect coronary artery stenosis compared to the targeted technique.\(^{[7]}\) However, in this meta-analysis, almost all studies of targeted MRCA (8 of 9 studies) used gradient echo sequence, whereas most studies of whole-heart MRCA (12 of 15) used SSFP sequence. Sequence type affects the accuracy of coronary artery assessment. SSFP sequence provides higher blood signal intensity, reduced motion artifacts, and superior vessel
sharpness that can be further enhanced when used with an optimized k-space sampling strategy such as radial sampling.\cite{28,29}

Although the whole-heart method is convenient to perform and requires less total examination time, targeted MRCA is more likely to yield high image quality and vessel sharpness, with relatively shorter acquisition time for imaging a single specific coronary artery as well as providing greater contrast-to-noise ratio.\cite{10} Overall, both methods have their own advantages, and could potentially be useful for clinical applications of coronary artery assessment. Our center has previously reported on the high accuracy of targeted MRCA to diagnose coronary artery stenosis compared to invasive coronary angiography with a sensitivity of 97.6\% and a specificity of 75\%.\cite{30}

**Prognostic Value of MRCA in Patients with CAD**

Unlike diagnostic data, evidence concerning the prognosis of MRCA is very limited. The study of 207 patients by Yoon et al. found that the presence of significant coronary artery stenosis using whole-heart MRCA was strongly associated with cardiac death and MACE based on univariate analysis.\cite{11} However, a small number of cardiac events in the study precluded a valid multivariate analysis for comparison of MRCA with other risk predictors. Given the lack of prognostic studies regarding targeted MRCA, our study was conducted based on the hypothesis that the targeted approach may have a prognostic role similar to the whole-heart technique. Additionally, we included MRCA into a routine clinical CMR protocol (functional study, LGE) to evaluate whether MRCA provides independent and incremental prognostic values.

Our study determined that 35.7\% of patients who underwent MRCA for assessment of CAD had significant coronary artery stenosis. The moderate prevalence of significant coronary artery stenosis in our study was comparable with previous reports.\cite{11,31} Patients with significant coronary artery stenosis had a higher prevalence of cardiac risk factors such as hyperlipidemia and current smoking. They were also more likely to have myocardial scarring. Concurring with Yoon et al., our data showed that patients with significant coronary artery stenosis had a substantially higher rate of hard cardiac events and MACE than those without significant stenosis.\cite{11} Targeted MRCA also demonstrated an independent and incremental prognostic value over clinical data, LVEF, and myocardial scarring to predict future cardiac events. This was a novel finding to show the advantages of MRCA in patients with CAD.

In our study, targeted MRCA had another benefit beyond the assessment of atherosclerotic CAD. MRCA was able to diagnose patients who had anomalous coronary arteries. This is a unique advantage of MRCA, specifically for children and young patients who need to avoid radiation exposure, while some also need serial CMR examinations.

Novel MRCA techniques to increase spatial resolution and decrease acquisition time are currently being developed, including 4-D whole-heart imaging and accelerated acquisition methods such as compressed sensing. These techniques may improve the accuracy and prognostic significance of MRCA.
Study Limitations

Our study had some limitations. Firstly, the study methodology was retrospective, and some confounding factors could not be completely eliminated. Secondly, our study had a relatively low event rate, and some degree of overfitting may have occurred in the multivariate analyses. This possibility was avoided by using a limited number of variables, and our results were consistent with a previous study.\textsuperscript{[11]} Thirdly, imaging of coronary stents and in-stent restenosis cannot be assessed directly by conventional MRCA because of local signal voids of the stents. Thus, evidence of MRCA in this population was limited. Finally, the prognostic value of MRCA when combined with a comprehensive CMR study including stress perfusion imaging remains unknown and requires further study.

Conclusion

This study demonstrated the prognostic value of significant coronary artery stenosis by non-contrast enhanced targeted MRCA in a larger group of patients with known or suspected CAD. MRCA may become an integrative part of comprehensive CMR assessment of CAD in the future.

List Of Abbreviations

CI = confidence interval

CAD = coronary artery disease

CCTA = coronary computed tomography angiography

CMR = cardiac magnetic resonance

ECG = electrocardiogram

HR = hazard ratio

LGE = late gadolinium enhancement

LV = left ventricular

LVEF = left ventricular ejection fraction

MACE = major adverse cardiovascular events

MI = myocardial infarction

MRCA = magnetic resonance coronary angiography

SSFP = steady state free precession
Declarations

Ethics approval and consent to participate

This study was approved by Siriraj Institutional Review Board (SIRB), Faculty of Medicine Siriraj Hospital, Mahidol University (Title: Prognostic value of comprehensive cardiac magnetic resonance imaging in patients with suspected coronary artery disease, certification of approval number: SI 175/2014). All methods involving human data were performed in accordance with the Declaration of Helsinki. The need for consent was waived by Siriraj Institutional Review Board (SIRB) due to its retrospective nature and as all personal identifying information was obliterated.

Consent for publication

Not applicable.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Author contributions

YK - (1) conception and design, analysis, and interpretation of data; (2) performance of experiments or therapy; (3) drafting of the manuscript or revising it critically for important intellectual content; and (4) final approval of the manuscript submitted.

RT - (1) performance of experiments or therapy; (2) final approval of the manuscript submitted.

TB - (1) conception and design, analysis, and interpretation of data; (2) drafting of the manuscript or revising it critically for important intellectual content; and (3) final approval of the manuscript submitted.

Acknowledgement

The authors would like to thank Mr. Dittapol Muntham, M.S. (Statistics) for statistical assistance.

References


Tables

Table 1. Baseline Characteristics of Patients with and without Significant Coronary Artery Stenosis.
<table>
<thead>
<tr>
<th></th>
<th>Total (n=389)</th>
<th>Significant Stenosis (n=139)</th>
<th>No Significant Stenosis (n=250)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>187 (48)</td>
<td>76 (55)</td>
<td>111 (44)</td>
<td>0.05</td>
</tr>
<tr>
<td>Age, years</td>
<td>68.1 ± 10.8</td>
<td>69.4 ± 9.9</td>
<td>67.3 ± 11.3</td>
<td>0.07</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>136.5 ± 18.9</td>
<td>139.9 ± 18.7</td>
<td>134.7 ± 18.9</td>
<td><strong>0.008</strong></td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td>73.8 ± 11.7</td>
<td>72.6 ± 12.3</td>
<td>74.4 ± 11.4</td>
<td>0.16</td>
</tr>
<tr>
<td>Heart rate, beats/minutes</td>
<td>77.5 ± 13.6</td>
<td>76.1 ± 14.1</td>
<td>78.2 ± 13.3</td>
<td>0.15</td>
</tr>
<tr>
<td>Clinical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>340 (87)</td>
<td>126 (91)</td>
<td>214 (86)</td>
<td>0.15</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>215 (55)</td>
<td>81 (58)</td>
<td>134 (54)</td>
<td>0.37</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>292 (75)</td>
<td>114 (82)</td>
<td>178 (71)</td>
<td><strong>0.02</strong></td>
</tr>
<tr>
<td>Stable coronary artery disease</td>
<td>61 (16)</td>
<td>45 (32)</td>
<td>16 (6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>12 (3)</td>
<td>11 (8)</td>
<td>1 (0.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Stroke</td>
<td>17 (4)</td>
<td>5 (4)</td>
<td>12 (5)</td>
<td>0.58</td>
</tr>
<tr>
<td>Current smoking</td>
<td>70 (18)</td>
<td>40 (29)</td>
<td>30 (12)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chest pain</td>
<td>133 (34)</td>
<td>39 (28)</td>
<td>94 (38)</td>
<td>0.06</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>62 (16)</td>
<td>18 (13)</td>
<td>44 (18)</td>
<td>0.23</td>
</tr>
<tr>
<td>Heart failure</td>
<td>33 (8)</td>
<td>13 (9)</td>
<td>20 (8)</td>
<td>0.65</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACEI or ARB</td>
<td>171 (44)</td>
<td>63 (45)</td>
<td>108 (43)</td>
<td>0.69</td>
</tr>
<tr>
<td>Antiplatelet</td>
<td>184 (47)</td>
<td>78 (56)</td>
<td>106 (42)</td>
<td><strong>0.01</strong></td>
</tr>
<tr>
<td>Beta blocker</td>
<td>186 (48)</td>
<td>67 (48)</td>
<td>119 (48)</td>
<td>0.91</td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>123 (32)</td>
<td>41 (30)</td>
<td>82 (33)</td>
<td>0.50</td>
</tr>
<tr>
<td>Nitrate</td>
<td>54 (14)</td>
<td>34 (25)</td>
<td>20 (8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Statin</td>
<td>196 (50)</td>
<td>81 (58)</td>
<td>115 (46)</td>
<td><strong>0.02</strong></td>
</tr>
<tr>
<td>CMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEDV index, ml/m²</td>
<td>47.3 ± 59.6</td>
<td>59.6 ± 47.0</td>
<td>40.4 ± 38.0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
LVESV index, ml/m²

<table>
<thead>
<tr>
<th></th>
<th>27.8 ± 24.9</th>
<th>34.9 ± 28.1</th>
<th>23.8 ± 22.0</th>
<th>&lt;0.001</th>
</tr>
</thead>
</table>

LVEF, %

<table>
<thead>
<tr>
<th></th>
<th>67.4 ± 14.1</th>
<th>63.1 ± 16.4</th>
<th>69.8 ± 12.1</th>
<th>&lt;0.001</th>
</tr>
</thead>
</table>

Late gadolinium enhancement

<table>
<thead>
<tr>
<th></th>
<th>81 (21)</th>
<th>64 (46)</th>
<th>17 (7)</th>
<th>&lt;0.001</th>
</tr>
</thead>
</table>

Number of coronary artery stenosis

<table>
<thead>
<tr>
<th></th>
<th>1-vessel</th>
<th>2-vessel</th>
<th>3-vessel</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1-vessel</td>
<td>66 (17)</td>
<td>66 (48)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2-vessel</td>
<td>49 (13)</td>
<td>49 (35)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3-vessel</td>
<td>24 (6)</td>
<td>24 (17)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Values are numbers (percentages) or mean ± standard deviation. **Bold** values are <0.05.

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CMR = cardiac magnetic resonance; LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume.

**Table 2.** Cardiac Events.

<table>
<thead>
<tr>
<th></th>
<th>Total (n=389)</th>
<th>Significant Stenosis (n=139)</th>
<th>No Significant Stenosis (n=250)</th>
<th>HR (95% CI)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac mortality</td>
<td>8 (2.1)</td>
<td>6 (4.3)</td>
<td>2 (0.8)</td>
<td>5.57 (1.12-27.61)</td>
<td>0.04</td>
</tr>
<tr>
<td>Non-fatal myocardial infarction</td>
<td>19 (4.9)</td>
<td>14 (10.1)</td>
<td>5 (2.0)</td>
<td>5.44 (1.96-15.13)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hospitalization for heart failure</td>
<td>34 (8.7)</td>
<td>19 (13.7)</td>
<td>15 (6.0)</td>
<td>2.43 (1.24-4.79)</td>
<td>0.01</td>
</tr>
<tr>
<td>Late revascularization</td>
<td>10 (2.6)</td>
<td>9 (6.5)</td>
<td>1 (0.4)</td>
<td>17.58 (2.23-138.85)</td>
<td></td>
</tr>
</tbody>
</table>

Values are numbers (percentages). **Bold** values are <0.05.

CI = confidence interval; HR = hazard ratio.

**Table 3.** Univariate and Multivariate Analyses of Hard Cardiac Events.
<table>
<thead>
<tr>
<th></th>
<th>Univariate Analysis</th>
<th></th>
<th></th>
<th>Multivariate Analysis</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>p-Value</td>
<td>HR (95% CI)</td>
<td>p-Value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.03 (0.45-2.34)</td>
<td>0.93</td>
<td>1.03 (0.45-2.34)</td>
<td>0.93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>1.01 (0.96-1.04)</td>
<td>0.69</td>
<td>1.01 (0.96-1.04)</td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure, per 1 mmHg</td>
<td>1.001 (0.97-1.02)</td>
<td>0.90</td>
<td>1.001 (0.97-1.02)</td>
<td>0.90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure, per 1 mmHg</td>
<td>0.98 (0.95-1.02)</td>
<td>0.56</td>
<td>0.98 (0.95-1.02)</td>
<td>0.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate, beats/minutes</td>
<td>1.01 (0.98-1.04)</td>
<td>0.51</td>
<td>1.01 (0.98-1.04)</td>
<td>0.51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.64 (0.38-6.99)</td>
<td>0.50</td>
<td>1.64 (0.38-6.99)</td>
<td>0.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1.09 (0.48-2.50)</td>
<td>0.82</td>
<td>1.09 (0.48-2.50)</td>
<td>0.82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>0.82 (0.32-2.09)</td>
<td>0.69</td>
<td>0.82 (0.32-2.09)</td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stable coronary artery disease</td>
<td>2.10 (0.82-5.34)</td>
<td>0.12</td>
<td>2.10 (0.82-5.34)</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>4.49 (1.33-15.11)</td>
<td><strong>0.02</strong></td>
<td>1.43 (0.37-5.59)</td>
<td>0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoking</td>
<td>1.21 (0.45-3.27)</td>
<td>0.70</td>
<td>1.21 (0.45-3.27)</td>
<td>0.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest pain</td>
<td>1.54 (0.67-3.50)</td>
<td>0.30</td>
<td>1.54 (0.67-3.50)</td>
<td>0.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>1.28 (0.47-3.44)</td>
<td>0.63</td>
<td>1.28 (0.47-3.44)</td>
<td>0.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>2.81 (1.04-7.59)</td>
<td><strong>0.04</strong></td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACEI or ARB</td>
<td>1.23 (0.54-2.80)</td>
<td>0.61</td>
<td>1.23 (0.54-2.80)</td>
<td>0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet</td>
<td>1.65 (0.71-3.82)</td>
<td>0.24</td>
<td>1.65 (0.71-3.82)</td>
<td>0.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta blocker</td>
<td>1.33 (0.58-3.05)</td>
<td>0.49</td>
<td>1.33 (0.58-3.05)</td>
<td>0.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>1.18 (0.50-2.80)</td>
<td>0.69</td>
<td>1.18 (0.50-2.80)</td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrate</td>
<td>2.91 (1.23-6.88)</td>
<td><strong>0.02</strong></td>
<td>1.34 (0.50-3.59)</td>
<td>0.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statin</td>
<td>1.34 (0.59-3.07)</td>
<td>0.48</td>
<td>1.34 (0.59-3.07)</td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEDV index, ml/m²</td>
<td>1.01 (1.001-1.01)</td>
<td><strong>0.01</strong></td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVESV index, ml/m²</td>
<td>1.01 (1.004-1.02)</td>
<td><strong>0.003</strong></td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF, %</td>
<td>0.96 (0.94-0.98)</td>
<td><strong>0.004</strong></td>
<td>0.99 (0.96-1.02)</td>
<td>0.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late gadolinium enhancement</td>
<td>4.75 (2.09-10.79)</td>
<td><strong>&lt;0.001</strong></td>
<td>1.78 (0.57-5.56)</td>
<td>0.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Significant coronary artery stenosis</td>
<td>5.52 (2.17-14.01)</td>
<td><strong>&lt;0.001</strong></td>
<td>3.35 (1.13-9.96)</td>
<td><strong>0.03</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bold** values are <0.05.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CI = confidence interval; CMR = cardiac magnetic resonance; HR = hazard ratio; LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume.

**Table 4.** Univariate and Multivariate Analyses of MACE.
<table>
<thead>
<tr>
<th></th>
<th>Univariate Analysis</th>
<th>Multivariate Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>p-Value</td>
</tr>
<tr>
<td>Male</td>
<td>1.22 (0.70-2.10)</td>
<td>0.47</td>
</tr>
<tr>
<td>Age, years</td>
<td>1.02 (0.99-1.04)</td>
<td>0.12</td>
</tr>
<tr>
<td>Systolic blood pressure, per 1 mmHg</td>
<td>1.00 (0.98-1.01)</td>
<td>0.99</td>
</tr>
<tr>
<td>Diastolic blood pressure, per 1 mmHg</td>
<td>0.97 (0.95-1.01)</td>
<td><strong>0.01</strong></td>
</tr>
<tr>
<td>Heart rate, beats/minutes</td>
<td>1.01 (0.98-1.02)</td>
<td>0.66</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.46 (0.58-3.68)</td>
<td>0.42</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1.03 (0.59-1.78)</td>
<td>0.91</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1.11 (0.57-2.16)</td>
<td>0.76</td>
</tr>
<tr>
<td>Stable coronary artery disease</td>
<td>2.09 (1.11-3.92)</td>
<td><strong>0.02</strong></td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>3.87 (1.53-9.74)</td>
<td><strong>0.004</strong></td>
</tr>
<tr>
<td>Current smoking</td>
<td>1.84 (1.01-3.35)</td>
<td><strong>0.04</strong></td>
</tr>
<tr>
<td>Chest pain</td>
<td>1.36 (0.78-2.35)</td>
<td>0.27</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>1.11 (0.56-2.22)</td>
<td>0.76</td>
</tr>
<tr>
<td>Heart failure</td>
<td>4.59 (2.52-8.37)</td>
<td><strong>&lt;0.001</strong></td>
</tr>
<tr>
<td>ACEI or ARB</td>
<td>1.34 (0.78-2.31)</td>
<td>0.28</td>
</tr>
<tr>
<td>Antiplatelet</td>
<td>1.14 (0.66-1.97)</td>
<td>0.62</td>
</tr>
<tr>
<td>Beta blocker</td>
<td>1.02 (0.59-1.75)</td>
<td>0.94</td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>0.64 (0.33-1.22)</td>
<td>0.18</td>
</tr>
<tr>
<td>Nitrate</td>
<td>1.89 (1.01-3.55)</td>
<td><strong>0.04</strong></td>
</tr>
<tr>
<td>Statin</td>
<td>1.11 (0.64-1.91)</td>
<td>0.70</td>
</tr>
<tr>
<td>LVEDV index, ml/m²</td>
<td>1.01 (1.005-1.01)</td>
<td><strong>&lt;0.001</strong></td>
</tr>
<tr>
<td>LVESV index, ml/m²</td>
<td>1.02 (1.01-1.02)</td>
<td><strong>&lt;0.001</strong></td>
</tr>
<tr>
<td>LVEF, %</td>
<td>0.96 (0.94-0.97)</td>
<td><strong>&lt;0.001</strong></td>
</tr>
<tr>
<td>Late gadolinium enhancement</td>
<td>4.62 (2.68-7.98)</td>
<td><strong>&lt;0.001</strong></td>
</tr>
<tr>
<td>Significant coronary artery stenosis</td>
<td>3.49 (1.98-6.14)</td>
<td><strong>&lt;0.001</strong></td>
</tr>
</tbody>
</table>

**Bold** values are <0.05.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CI = confidence interval; CMR = cardiac magnetic resonance; HR = hazard ratio; LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; MACE = major adverse cardiac events.

Figures

Figure 1
Images illustrating MRCA findings in a 62-year-old man presenting with chest pain. Maximum intensity projection images showed significant stenosis in the proximal part of the left anterior descending artery (red arrow), left circumflex artery (green arrow), and right coronary artery (yellow arrow). MRCA = magnetic resonance coronary angiography.

Figure 2

Kaplan-Meier survival curves for hard cardiac events (A) and MACE (B). MACE = major adverse cardiac events.

Figure 3

Incremental prognostic value of LVEF, LGE, and MRCA for the prediction of hard cardiac events (A) and MACE (B). Clinical = age, male gender, history of heart failure, and previous myocardial infarction. LGE =
late gadolinium enhancement; LVEF = left ventricular ejection fraction; MACE = major adverse cardiovascular events; MRCA = magnetic resonance coronary angiography.

**Figure 4**

MRCA images showing a malignant-type anomalous coronary artery in a 40-year-old man with chest pain during exercise (right coronary artery ostium-red arrow, left main coronary artery-yellow arrow, and left coronary cusp of the aortic valve-green arrow). MRCA = magnetic resonance coronary angiography.